Back to News
Market Impact: 0.15
Aligos Therapeutics To Present HBV, HDV Programs At AASLD 2026
Source: Nasdaq
Healthcare & Biotech
Aligos Therapeutics said five abstracts were accepted for presentation at the AASLD Liver Meeting 2026, scheduled for November 5–9, 2026. The announcement provides no study results or other clinical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
ALGS0.45
More News
- Why is Telix Pharmaceuticals stock rallying today?
- Why is Natera stock sliding today?
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
- Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD
- LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
- Why is Illumina stock sliding today?